Find a laboratory at the Crick.
Find links to current vacancies, and information about recruitment to various types of role.
We collaborate with local residents, community organisations and partners
A collection of poems inspired by the words of those who have been vaccinated within the Crick, the reflections of the volunteers working at the vaccination centre, and the experiences our local communities.
Exhibition entry: Available to view between May and August 2021
Crick researchers are working at the forefront of the scientific response to answer some of the most urgent questions about the SARS-CoV-2 pathogen, from how we can improve testing, to why it’s deadly in some people but causes no symptoms in others.
The Francis Crick Institute is working at the forefront of the scientific response to coronavirus, volunteering expertise and facilities to help tackle the COVID-19 pandemic.
The CAPTURE study aims to investigate the immune response to SARS-CoV-2 in cancer patients and untangle the complex relationship between the host, the cancer, the virus and the anti-cancer therapy.
The Francis Crick Institute has repurposed its laboratory facilities to become a COVID-19 testing facility, to help combat the spread of infection and allow key workers to perform lifesaving duties and remain safe.
The COVID-19 outbreak requires a concerted research effort - at the Crick researchers are looking at how the virus interacts with our body and how the virus leapt from animals to humans.
Patients with blood cancers such as leukaemia vary in their immune response to COVID-19 and can struggle to clear infection for very many weeks.
Researchers at the Crick, King’s College London and Guy's and St Thomas' NHS Foundation Trust, have found a common immune signature in the blood of patients with COVID-19, which could be used to predict how severely ill a patient will become, aiding patient management.
Researchers at the Crick and Charité – Universitätsmedizin Berlin have identified 27 protein biomarkers that could be used to predict whether a patient with COVID-19 is likely to become severely ill with the disease.
Researchers at the Crick have identified a variant of the SARS-CoV-2 cell receptor ACE2, which is driven by antiviral interferon signals. The virus is not able to bind to this variant, dispelling concerns that interferon-based treatments could be inadvertently helping it spread more quickly in the body.
Researchers at the Crick have validated a method to test for SARS-CoV-2. The team have shared their protocols for using this promising method and how to report results to health authorities.
A partnership between The Francis Crick Institute, Health Services Laboratory (HSL), Institute of Cancer Research and University College London Hospital NHS Trust.